G1T 38

Drug Profile

G1T 38

Alternative Names: G1T 38

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator G1 Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer
  • Phase I Cancer

Most Recent Events

  • 01 Jan 2017 Phase-I/II clinical trials in Breast cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in Georgia, Moldova (PO) (NCT02983071)
  • 01 Dec 2016 G1 Therapeutics plans a phase I/II trial for Breast cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in United Kingdom, Bulgaria, Czech Republic, Georgia, Moldova and Romania (PO) (NCT02983071)
  • 01 May 2016 Phase-I clinical trials in Cancer (In volunteers) in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top